Pharmacyclics Gains ‘Breakthrough’ Status for Cancer Drug

Pharmacyclics Inc., a drugmaker developing an experimental therapy for blood cancers, won “breakthrough” status from U.S. regulators for the medicine that may lead to quicker marketing approval.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.